Strand Therapeutics vs Prime Medicine
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $153M Series B (Aug 2025). $256M total. Programmable mRNA with SignalLock tumor-sensing logic gates. STX-003 IV delivery entering clinic 2026. Phase 1 confirmed CR at ASCO 2025.
About
Strand Therapeutics is developing programmable mRNA — modified messenger RNA that incorporates synthetic gene circuits (logic gates) that restrict therapeutic protein expression to the tumor microenvironment. The company raised $153 million in Series B financing in August 2025, bringing total funding to $256 million at a ~$571 million valuation. Strand presented Phase 1 data at ASCO 2025 showing a confirmed complete response for STX-001, and its STX-003 program — which uses intravenous delivery rather than intratumoral injection — is entering clinical testing in 2026.
Nasdaq-listed (PRME). $191M cash runway into 2027. IND for Wilson's Disease H1 2026. AATD IND mid-2026. $3.5B+ BMS collaboration. CGD Phase 1 showing rapid function restoration after single infusion.
About
Prime Medicine is a publicly-traded (Nasdaq: PRME) clinical-stage biotech developing Prime Editing — the most versatile and precise gene editing technology currently entering clinical trials, capable of making all 12 possible base-pair changes, small insertions, and deletions in DNA without double-strand breaks. The company has $191 million in cash runway into 2027, INDs planned for Wilson's Disease and Alpha-1 antitrypsin deficiency (AATD) in 2026, and a $55 million upfront collaboration with Bristol Myers Squibb worth up to $3.5 billion in milestones.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.